Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
A phase 1/2 trial of Asciminib, Dexamethasone, Vincristine, Blinatumomab, Methotrexate and Cytarabine in acute lymphoblastic leukaemia, run by Novartis Pharmaceuticals, now recruiting.
Overview
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) is a phase 1/2 interventional study registered as NCT07387926 by Novartis Pharmaceuticals, with 50 participants planned, started 2026-07-05 and due to reach its primary completion in 2033-09-19. Interventions recorded: Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone, Vincristine, Blinatumomab and Methotrexate (intrathecal).
Similar pages
not linked directly; found by shared links- TrialStudy to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Shares Asciminib, Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialAsciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
Shares Asciminib, Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialOpen-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
Shares Asciminib, Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialStudy to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Shares Asciminib, Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialA Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
Shares Asciminib, Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialStudy of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
Shares Advanced Accelerator Applications (Novartis), Acute lymphoblastic leukaemia and the tag pipeline.
- TrialA Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Shares Blinatumomab, Acute lymphoblastic leukaemia and the tag pipeline.
- TrialA Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Shares Blinatumomab, Acute lymphoblastic leukaemia and the tag pipeline.